In the first three quarters of 2026, Chinese companies signed outbound technology-licensing deals for innovative drugs worth roughly US$130 billion, according to figures disclosed by NDRC official Zuo Gang and reported by Yicai. That is within about US$5.7 billion of the full-year 2025 record of US$135.7 billion, with a quarter of the year still to run. McKinsey analysis cited in the same report says the share of licensing deals sourced from China among the world's ten largest pharmaceutical companies rose from 15 percent in 2023 to about 50 percent in the first half of 2026. For a patient reading this from the United States, the United Kingdom, Australia or the Gulf, the practical consequence is worth stating plainly: China increasingly is where a new oncology or autoimmune medicine is developed, first administered to patients, and sometimes used clinically before the same asset is marketed in Western countries.
This article is deliberately careful about what that does and does not mean. We are not going to publish a list of drug names that are "only available in China", because approval status, indications and hospital stocking change faster than any static list can track, and because a wrong name in a health article is not a typographical error but a decision that could send someone across the world. What we can do is show you how the deal-driven pipeline works, how to verify a specific medicine yourself, and how to decide whether a trip to China is justified by your actual clinical situation.
What the 2026 licensing numbers really tell a patient
The headline totals are large, and the fine print matters more than the headline. Industry data from PharmCube cited in the Yicai report shows that outbound licensing deals in the first half of 2026 were worth US$99.7 billion in total contract value, while upfront payments received came to nearly US$5 billion, roughly 5 percent of the contracted amount. Most of the money is contingent on trials succeeding. That single ratio explains the tone you should bring to any press release: it describes a company's belief about a future medicine, not a shelf you can order from today.
A concrete example from the week of writing this. On 4 November 2026, Sino Biopharm announced an outbound licensing collaboration with Boehringer Ingelheim covering six preclinical programmes in next-generation oncology, with US$358 million in upfront and near-term payments and milestone payments of up to US$7 billion in total, as summarised in financial coverage of the announcement. Because the coverage is a secondary financial report, we would verify the exact terms against the company's own published announcement before repeating them. The clinically useful part is the structure: preclinical assets that a multinational has taken on will normally be developed across several countries, which means trial sites, future filings, and eventually hospital availability in China and elsewhere move on overlapping schedules rather than one global date.
Two patterns follow from this for international patients. First, when a Chinese developer runs its own pivotal trials domestically, Chinese patients can be treated during the programme rather than after it; our cancer treatment in China coordination work most often involves this category, where an option exists here and not yet at home. Second, when a multinational licenses the asset, the earliest human data may still come from Chinese sites while Western access lags by years. Categories that patients ask us about most often include cellular therapies such as CAR-T, antibody-drug conjugates, bispecific antibodies in oncology, and biologics or immune-directed therapies in autoimmune disease. Each of these is a class, not a guarantee; ask which specific product, at which hospital, under which approval.
Three distinctions that prevent most disappointment
- A signed deal is not an available drug. Milestones are paid on success, and most early programmes do not reach patients.
- Approval is not reimbursement, and reimbursement is not stocking. A medicine can be registered in China and still not be on the formulary of the department you intend to visit.
- Availability in China is not suitability for you. Stage, prior treatment, organ function and performance status decide eligibility, not the drug's novelty.
A verification framework before you book a flight
When a patient sends us a drug name, we work through five checks. The same sequence is worth applying to anything you read in the press.
- Regulatory status. Confirm the approved generic name, the marketing authorisation holder and the exact indication wording. Marketing status and indication can be narrower than the news implies.
- Prescriber and setting. Ask which department at which hospital prescribes it, whether it requires inpatient administration and monitoring, and how many days on site that implies. Our hospital appointment service in Shanghai exists mainly because this question is hard to answer from abroad.
- Evidence for your specific disease. Ask for the trial in which the drug was used in your tumour type or condition, and what it measured. Novel is not the same as proven for you.
- Payment route. City-custom commercial medical plans are the most realistic supplement for high-cost specialty drugs. In the report on 2026 upgrades, Tianjin's Huiminbao moved to age-tiered premiums of 130, 140 and 150 yuan and expanded its high-cost specialty drug list to 50 items, while in Hangzhou a designated-hospital internet prescribing route was described with no deductible and an 80 percent reimbursement rate. Whether such a policy covers a non-national or a short-visit patient is a separate eligibility question that must be confirmed with the insurer in writing, not inferred from a news article.
- Logistics and follow-up. Many advanced therapies need repeat visits, laboratory monitoring, and a plan for adverse events after you go home. Any treatment plan must be assessed in person by a licensed physician, and a physician in your home country should be part of the loop.
Access pathways compared
| Pathway | What it looks like in practice | Realistic timing signal | What to verify first |
|---|---|---|---|
| Approved medicine prescribed at a Chinese hospital | Outpatient or inpatient treatment under a specialist; the most common route for patients travelling for care | Available now, subject to stock | Exact indication, which hospitals hold it, administration and monitoring schedule |
| Treatment inside a clinical trial run in China | Free protocol-mandated drug and tests, strict eligibility and visit requirements | Months, driven by open slots and criteria | Trial registration, inclusion criteria, whether foreign patients may enrol |
| Approved drug with commercial specialty-drug cover | Payment partly handled by a city-custom or private policy rather than basic insurance | Available now, cover-dependent | Written confirmation that your nationality and residence status are eligible |
| Newly announced licensing deal | No patient access; development and future filings | Years, and not certain to arrive | The company's own announcement, not a secondary financial report |
Costs, and what we will not quote
We will not paste a number into a health article and let it age into a false promise. Prices for advanced therapies, inpatient stays and specialty drugs are set by the treating hospital and change with formulation, dosing band and length of stay, so the workable answer is always the institution's current written quote for your specific plan. What we can tell you is where to look: our CAR-T therapy cost page and proton therapy guide describe the shape of those expenses and what drives them, and a baseline health checkup in Shanghai is frequently the least expensive first step, because it converts a vague referral into stageable data that specialists can act on. Supportive care during treatment is a separate conversation, and some patients integrate Traditional Chinese Medicine for symptom management alongside oncology care, always with the treating specialist informed about every product being taken.
One non-medical cost decides more trips than people expect: time. Visa categories, entry documents and permitted length of stay are covered in our China medical visa guide, and the wider logistics are set out in the complete medical tourism guide to China. A plan that assumes two visits when the protocol needs five is a plan that fails quietly.
Who should consider this, and who should not
Coming to China for a medicine makes sense when your standard local options are exhausted or contested, when the specific drug can be confirmed as prescribed at a named hospital, and when the monitoring plan after you fly home is agreed. It makes little sense when the only evidence is a licensing headline, when a preclinical programme is described to you as a treatment, or when someone promises an outcome. Be sceptical of any provider who quotes results rather than a diagnostic and eligibility process.
The pipeline itself is the useful news: capital, development capacity and early patient access are shifting toward China, and the gap between "announced" and "available" is where patients get hurt or get helped.
If you want a concrete answer for your own case, send us your diagnosis, staging, pathology and prior treatments through case evaluation. We will tell you honestly whether a medicine appears reachable in China today, which hospitals realistically manage that condition, and what the visit schedule would look like. For questions about scheduling, documents or payment routes, use the inquiry form — OriEast provides medical translation, hospital registration and day-to-day coordination so that the clinical decision and the logistics are not made by the same stressed person on a tourist Wi-Fi connection.